Wnt/β-catenin pathway
Overview
The Wnt/β-catenin pathway is a conserved cell-signaling cascade that regulates embryonic development, tissue homeostasis, stem cell behavior, and cell fate decisions. In the canonical pathway, Wnt ligand stimulation stabilizes β-catenin, allowing it to accumulate and translocate to the nucleus, where it cooperates with transcriptional regulators such as TCF4 to drive expression of target genes including CCND1 and MYC proto-oncogene (MYC). When the pathway is not appropriately controlled, β-catenin signaling can become aberrantly activated and contribute to tumorigenesis, altered differentiation, fibrosis, and other disease processes.
In biomedical research, the pathway is frequently studied as both a mechanistic node and a therapeutic target. Recent studies in colorectal cancer, lung adenocarcinoma, breast cancer, skeletal aging, and fibrosis-associated models have examined how modulation of Wnt/β-catenin signaling intersects with inflammatory signaling, oxidative stress, ferroptosis, ER stress, ciliogenesis, and drug resistance. The pathway is also relevant in bone biology, where WNT signaling supports bone health and inhibitors such as Sclerostin can influence skeletal deterioration.
Recent Publications Focus
Recent studies demonstrate the Wnt/β-catenin signaling pathway as a critical regulator of tissue regeneration and disease progression across multiple organ systems. In bone regeneration, researchers identified CCN3+ mesenchymal stem cells recruited by magnesium-enriched microenvironments that promote early osteogenesis via the Wnt/β-catenin pathway and suppress M1 macrophage polarization through PTN secretion 42204979May. Novel ten-membered lactone compounds, particularly compounds 4 and 8, significantly enhanced osteoblastogenesis by specifically activating the Wnt/β-catenin pathway and alleviated dexamethasone-induced osteoporosis in zebrafish models 41865565Mar. Microarray analysis of skeletal aging revealed microRNA networks that modulate WNT pathway signaling, with miR-183-5p identified as a shared upregulated microRNA regulating Wnt pathway genes across aging contexts; neutralization of Sclerostin, an endogenous Wnt pathway inhibitor, further revealed microRNA-dependent mechanisms suppressing bone metabolism during accelerated aging 42183846May. In neural regeneration, electroacupuncture facilitated spinal cord injury recovery by upregulating DHCR24 expression, which activated Wnt signaling pathway to reduce neuronal apoptosis and suppress neuroinflammation-associated microglial activation 42390651Jul.
Multiple cancer studies identify dysregulation of Wnt/β-catenin pathway as a driver of malignant progression and therapeutic resistance. In hepatocellular carcinoma, the F9 protein acts as a tumor suppressor by interacting with SERPINC1 to inhibit Wnt/β-catenin signaling, with F9-targeting strategies identified as a promising avenue for precision therapy 42243437Jun. In breast cancer, nuclear localization of XIAP promotes cell proliferation and chemoresistance through Wnt/β-catenin pathway activation coupled with suppression of the tumor suppressor IGFBP6, establishing an IGFBP6/Wnt regulatory axis associated with drug resistance 42069172May. Oral squamous cell carcinoma progression is facilitated by PRDX4-mediated activation of Wnt/β-catenin signaling 42049339Apr. In colorectal cancer, multiple complementary strategies suppress the Wnt/β-catenin pathway: dual inhibition of TROP2 and PERK enhanced suppression of ER stress and the pathway to overcome antibody-drug conjugate resistance 42030933Apr, while novel 8-sulfonamidoquinoline derivatives inhibited the pathway downstream of NF-κB by binding P65 41763019Feb. Tankyrase inhibitors (TNKS1/2 inhibitors such as Basroparib/STP1002) show potent and selective suppression of Wnt/β-catenin pathway signaling with sub-nanomolar enzymatic inhibition and excellent pharmacological properties for potential monotherapy or combination approaches in Wnt-driven Cancers 41565125Jan. In lung adenocarcinoma, artesunate reversed gefitinib resistance by coupling ferroptosis induction with Wnt/β-catenin pathway suppression through increased GSK3β and p-β-catenin expression while decreasing β-catenin, TCF4, Cyclin D1, and c-MYC proto-oncogene (MYC) levels 41967624Apr.
Metabolic and inflammatory disease contexts also involve Wnt/β-catenin pathway dysregulation. Adzuki bean saponin and its bioactive component soyasaponin Ba achieved anti-obesity effects through upregulation of Wnt/β-catenin signaling, offering potential for developing phytochemical-based therapeutics to combat metabolic disease 42248912Jun. Environmental exposure to food chain-transferred nanoplastics induced multi-organ toxicity by activating Wnt and TGF-β signaling through dysregulation of MTOR and FN1, triggering oxidative stress and organ fibrosis across cardiovascular and metabolic systems 42103696May. Traditional Chinese medicine approaches are being validated through transcriptomic analysis, with the Shenqiyichang decoction demonstrating colorectal cancer suppression via Wnt/β-catenin pathway modulation 41786058Mar.
What Changes, What Holds
1. Wnt signaling is now implicated in regeneration, immune remodeling, and neural repair beyond its established developmental and homeostatic roles
NEW DIRECTION These studies extend the pathway’s relevance into tissue regeneration and injury recovery, which the Overview does not yet cover. They also suggest that Wnt/β-catenin activity can be coupled to macrophage polarization control and neuroprotection, adding context-specific repair functions rather than revising the core canonical mechanism. The evidence is still preclinical and mechanistically fragmented, so the main update is breadth of biology, not a replacement of the established signaling model 42204979May42390651Jul.
2. Wnt/β-catenin remains a central cancer resistance axis, but new upstream regulators and inhibitors sharpen the therapeutic map
REINFORCES These papers strengthen the existing view that aberrant Wnt/β-catenin signaling drives tumor progression and drug resistance across multiple Cancers. What changes is not the direction of the biology but the list of actionable nodes: additional suppressors, activators, and pathway-blocking compounds now sit upstream or downstream of the canonical β-catenin/TCF program. The mixed set of findings supports continued therapeutic targeting, while leaving open which intervention points will prove most durable in patients 42243437Jun42069172May.
3. Wnt/β-catenin is expanding as a metabolic and toxicologic response pathway, not only a developmental or cancer pathway
NEW DIRECTION These findings add roles in obesity control and nanoplastic-associated organ injury, areas the Overview does not address. That broadens the pathway’s conceptual footprint from tissue maintenance and disease progression into metabolic regulation and environmental toxicity, with oxidative stress and fibrosis emerging as linked downstream consequences. The colorectal cancer transcriptomic result also reinforces pathway modulation as a therapeutic strategy, but the main update is that Wnt/β-catenin now appears relevant to exposures and metabolic phenotypes beyond the baseline’s established disease set 42248912Jun42103696May.
Overview update candidates: regeneration and repair roles; additional cancer resistance regulators and inhibitors; metabolic and environmental toxicity contexts.
wnt/β-catenin pathway
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding wnt/β-catenin pathway are described as follows:
- accelerated skeletal aging (Other) — 1 paper: PMIDs 42183846
- adenocarcinoma of the lung (Disease) — 1 paper: PMIDs 41967624
- Advanced Colorectal Cancer (Disease) — 1 paper: PMIDs 42030933
- Ammosamide B (Other) — 1 paper: PMIDs 41763019
- cellular senescence (Biological Process) — 1 paper: PMIDs 42183846
- critical-sized bone defects (Disease) — 1 paper: PMIDs 42204979
- cuproptosis (Biological Process) — 1 paper: PMIDs 42041155
- electroacupuncture (Therapy) — 1 paper: PMIDs 42390651
- endoplasmic reticulum (ER) stress (Biological Process) — 1 paper: PMIDs 42030933
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (Therapy) — 1 paper: PMIDs 41967624
- first-generation inhibitors (Other) — 1 paper: PMIDs 41795344
- HBV-HCC (Disease) — 1 paper: PMIDs 42243437
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study wnt/β-catenin pathway:
- 1H-pyrrolo[2,3-b]pyridine (Chemical) — 1 paper: PMIDs 41818865
- AZD5305 (Chemical) — 1 paper: PMIDs 41795344
- beagle femoral condyle defect model (Organism) — 1 paper: PMIDs 42204979
- bone-marrow mesenchymal stem cells (MSCs) (Cell Line) — 1 paper: PMIDs 42204979
- breast cancer cell line models (Cell Line) — 1 paper: PMIDs 42069172
- BV2 microglia (Cell Line) — 1 paper: PMIDs 42390651
- CCND1 (Gene) — 1 paper: PMIDs 41967624
- CRC preclinical models (Organism) — 1 paper: PMIDs 42030933
- CRISPR-Cascade (Technology) — 1 paper: PMIDs 42203510
- CTRP (Other) — 1 paper: PMIDs 42243437
- dexamethasone (Therapy) — 1 paper: PMIDs 41865565
- doxorubicin (Therapy) — 1 paper: PMIDs 42069172
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to wnt/β-catenin pathway include:
- NQO1 (Gene) — 2 papers: PMIDs 42103696, 41786058
- 11b (STP1002, Basroparib) (Therapy) — 1 paper: PMIDs 41565125
- Activating transcription factor 4 (Protein) — 1 paper: PMIDs 42030933
- Adzuki bean saponin (Therapy) — 1 paper: PMIDs 42248912
- apolipoprotein E4 (Protein) — 1 paper: PMIDs 42103696
- arachidonic acid pathway (Pathway) — 1 paper: PMIDs 42248912
- artesunate (Therapy) — 1 paper: PMIDs 41967624
- BRD4 (Protein) — 1 paper: PMIDs 41763019
- catalase (Protein) — 1 paper: PMIDs 42103696
- catenin beta 1 (Gene) — 1 paper: PMIDs 41961207
- CDK6 (Protein) — 1 paper: PMIDs 41795344
- cellular response to DNA damage stimulus (Biological Process) — 1 paper: PMIDs 42030933
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with wnt/β-catenin pathway include:
- glucose and lipid metabolism (Biological Process) — 2 papers: PMIDs 42248912, 42103696
- tumor cell apoptosis (Biological Process) — 2 papers: PMIDs 41818865, 41763019
- 50% inhibition concentration (IC50) (Clinical Metric) — 1 paper: PMIDs 41795344
- ADME properties (Other) — 1 paper: PMIDs 41565125
- Allograft inflammatory factor 1 (Gene) — 1 paper: PMIDs 42390651
- anti-obesity effects (Biological Process) — 1 paper: PMIDs 42248912
- antitumor activity (Clinical Metric) — 1 paper: PMIDs 41818865
- biomechanical integration (Clinical Metric) — 1 paper: PMIDs 42204979
- body axis abnormalities (Clinical Metric) — 1 paper: PMIDs 42203510
- cardiovascular disease (Disease) — 1 paper: PMIDs 42103696
- CCN3+ MSCs (Gene) — 1 paper: PMIDs 42204979
- CCR7 (Protein) — 1 paper: PMIDs 42390651
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding wnt/β-catenin pathway are summarized below:
- 8-sulfonamidoquinoline derivatives (Chemical) — 1 paper: PMIDs 41763019
- Age-related osteogenic failure (Disease) — 1 paper: PMIDs 41865565
- anti-cancer molecular mechanisms (Other) — 1 paper: PMIDs 41786058
- artesunate (Therapy) — 1 paper: PMIDs 41967624
- catenin beta 1 (Gene) — 1 paper: PMIDs 41961207
- cellular and developmental processes (Other) — 1 paper: PMIDs 42203510
- chemo-immunotherapeutic strategy (Other) — 1 paper: PMIDs 42041155
- colon cancer liver metastasis (Disease) — 1 paper: PMIDs 41763019
- combination regimens (Other) — 1 paper: PMIDs 42030933
- critical bone defects (Disease) — 1 paper: PMIDs 42204979
- CTNNB1 gene rs1798802 locus (Gene) — 1 paper: PMIDs 41961207
- cuproptosis tolerance (Biological Process) — 1 paper: PMIDs 42041155